Vera Therapeutics Q3 net loss $20.1M ($0.45/diluted); cash $159.9M; hematuria resolution data at ASN

Vera Therapeutics, Inc.

2023-Q3 EPS reported -$1.67

Net loss of $20.1M ($0.45 per diluted share) vs $24.7M ($0.91) in Q3 2022.
Cash, cash equivalents and securities $159.9M; cash burn $67.0M in nine months.
Phase 2b OLE eGFR and proteinuria data expected Q1 2024; pivotal Phase 3 ORIGIN 3 enrolling.
At ASN Kidney Week: 80% of atacicept patients achieved hematuria resolution vs 5% placebo.
Enrollment of Phase 3 ORIGIN 3 estimated to complete H2 2024; topline data H1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vera Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $20.1 million, EPS $0.45.

Period: the third quarter ended September 30, 2023
Net income: $20.1 million
EPS: $0.45
Result: reported results

Exact text from the filing

For the quarter ended September 30, 2023, the company reported a net loss of $20.1 million, or a net loss per diluted share of $0.45

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061548

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.